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Introduction
Streptococcus pyogenes (group A streptococcus) is a Gram-positive bacterium that causes some of the most common infections in humans [1] . With regard to nosocomial infections, the subject of this issue of Vaccine, it is of particular interest that S.
pyogenes caused the classical example of such infections, the epidemics of puerperal fever (childbed fever) that resulted in the death of numerous women during the 18 th and 19 th centuries. Although puerperal fever is now rare, it remains an important example of an infectious disease that emerged because of changes in society, in this case the construction of large maternity hospitals where the disease was acquired.
In addition to its importance as a pathogen, S. pyogenes is an attractive model system for analysis of some key problems in microbial pathogenesis. For example, S.
pyogenes has unique advantages for studies of antigenic variation, a phenomenon of major importance in vaccine development. Moreover, S. pyogenes is an interesting system for analysis of phagocytosis resistance, a common and important microbial virulence mechanism. This short review focuses on the properties of two S. pyogenes surface proteins, the M protein, which confers resistance to phagocytosis, and the R28 protein, which has been implicated in the pathogenesis of puerperal fever. In addition,
we will comment on a general problem that may complicate attempts to develop vaccines against a human pathogen such as S. pyogenes.
Streptococcus pyogenes
The two most common infections caused by S. pyogenes are acute tonsillitis ('strep throat') and the skin infection impetigo. During the last two decades, S. pyogenes has also emerged as the cause of a streptococcal toxic shock syndrome (STSS) with high mortality [1] . Importantly, infection with S. pyogenes is occasionally followed by one of two non-suppurative sequelae that may be due to autoimmunity, acute rheumatic fever (ARF) and acute post-streptococcal glomerulonephritis (APSGN). ARF is a major cause of acquired heart disease in developing countries and unexpected outbreaks occurred in the US in the 1980s, but like APSGN this disease is presently uncommon in the Western world [1] .
Remarkably, resistance to penicillin has never been described for S. pyogenes, a fact that simplifies treatment of infections and limits spread of the pathogen.
Nevertheless, development of a vaccine against this common pathogen is highly desirable, because S. pyogenes infections cause great costs to society and because a vaccine would be expected to reduce the incidence of ARF.
M protein and its role in phagocytosis resistance
The most extensively studied virulence factor of S. pyogenes is the surface M protein, identified already in the 1920s through the classical work of Rebecca Lancefield [2] .
The M protein inhibits phagocytosis by human neutrophils and allows S. pyogenes to grow rapidly in whole human blood [3] . In addition, M protein may have other functions, such as promoting adhesion to human epithelial cells [4] .
Several lines of evidence indicate that M protein plays a major role in human infections [3] . For example, recent studies in a primate model of S. pyogenes infection demonstrated that M protein promotes pharyngeal colonization, a feature that may be explained by its antiphagocytic property and/or by its ability to promote adhesion to epithelial cells [5] . Importantly, all clinical isolates of S. pyogenes express M protein, which occurs in >120 different types [6] . The M protein is stable within a single strain, but exhibits extensive sequence variability between strains, in particular in the Nterminal so-called hypervariable region (HVR), which determines the M type of the strain. Antibodies directed against the HVR are protective and the immunity is type-specific [3, 7] . In other words, M protein exhibits antigenic variation. This antigenic variation has so far precluded the development of a vaccine based on M protein.
The mechanism by which M protein inhibits phagocytosis has remained unclear, and the extensive sequence variability in the HVR has made it difficult to understand how this region could have the specific function to prevent phagocytosis. A clue to this problem was obtained through the finding that many HVRs specifically bind the same ligand, in spite of the extreme sequence variability between different HVRs. The bound ligand is human C4b-binding protein (C4BP) [8, 9] , a ~570 kDa plasma protein that inhibits activation of the classical pathway of complement activation [10, 11] . More than 50% of all S. pyogenes strains bind C4BP [12] , and all available evidence indicates that C4BP binds to the HVR of the M protein expressed by these strains [8, 9] . It is important to note, however, that many M proteins do not bind C4BP, and the exact molecular function of the HVR in these M proteins remains unknown.
We have used the M22 protein as a model system to study M protein function (Fig. 1) . The antiphagocytic property of this M protein may be explained as cooperation between two variable ligand-binding regions [13] . The HVR binds human C4BP and an adjacent semi-variable region (SVR) binds human IgA-Fc. The HVR makes an important contribution to phagocytosis resistance because bacteria-bound C4BP retains its ability to inhibit complement activation, thereby preventing opsonization due to complement deposition [13, 14] . Surprisingly, S. pyogenes lacking M protein activates the classical complement pathway even in normal human serum. This may explain why S. pyogenes exploits human C4BP for protection against complement activation [13] .
The SVR, which binds human IgA-Fc [15] , also makes an important contribution to phagocytosis resistance [13] , but the mechanism by which this region contributes to virulence is not clear. Possibly, the IgA-binding region acts by inhibiting the binding of IgA-Fc to the human IgA-receptor CD89 on phagocytes, thereby interfering with IgA effector functions [16] .
Importantly, the model shown in Fig. 1 can explain the existence of "protective"
and "non-protective" epitopes in M protein. Such epitopes were first described by Jones and Fischetti [17] , who showed that a mAb directed against the HVR of the M6 protein was protective (i.e. it blocked the antiphagocytic function of this M protein), while a mAb directed against the conserved C-repeat region was non-protective. We have confirmed this finding using polyclonal antibodies directed against different parts of the M22 protein, and find that protective antibodies block binding of the two ligands C4BP
and IgA, while non-protective antibodies do not have this property [13] . Thus, the key property of a protective antibody may be its ability to inhibit binding of ligand (s) readily be studied in soluble form and different ligand-binding regions can be studied as synthetic peptides [9, 18] . The evolution of extreme sequence divergence in the Nterminal region of M proteins is of considerable interest, because the variability appears to be at least as great as that observed in HIV-1 and influenza virus [9] .
In summary, our studies of the M22 protein indicate that the antiphagocytic property of this protein may be fully explained through its ability to bind two components of the humoral immune system, C4BP and IgA [13, 14] . This finding provides the first molecular explanation for the ability of M protein to confer phagocytosis resistance. It may appear surprising that plasma proteins play an essential role in infections caused by S. pyogenes, a pathogen that usually causes infections on mucosal surfaces. However, a plasma exudative response contributes to a first-line defense system [19] and neutrophils are recruited to the site of an infection, so it seems likely that the most important interactions between S. pyogenes and the human immune system occur on mucosal surfaces. An important subject for future studies will be to analyze how phagocytosis resistance is conferred by M proteins that do not bind C4BP
and/or IgA.
Puerperal fever and the R28 protein
In the 18 th and 19 th centuries, numerous women died from puerperal fever (childbed fever), the disease that was the subject of the classical studies of Semmelweis and caused one of the major controversies in medical history [20, 21] . It is now generally accepted that puerperal fever was due to transfer of bacteria to women in labour by attending hospital physicians, who had previously performed autopsies or examined other patients. The epidemics of puerperal fever were due to S. pyogenes infections [22] and the clinical picture was probably similar to that of the recently identified streptococcal toxic shock syndrome (STSS), including shock and multiorgan failure [1] .
Although puerperal fever is now rare, studies of this disease are of interest because it represents the classical example of a nosocomial infection and of an emerging infectious disease caused by changes in society. Virtually nothing is known about molecular mechanisms in puerperal fever, but an epidemiological study in Britain showed that the surface protein R28 was common among S. pyogenes strains isolated from recent outbreaks of puerperal fever, but was found in only a minority of pharyngitis strains [23] . This over-representation of R28-expressing strains among puerperal fever isolates led us to hypothesize that the R28 protein played an important role in the epidemics of puerperal fever [24] . For obvious reasons, S. pyogenes isolates from the 18 th and 19 th century epidemics of puerperal fever were not available for characterization, but analysis of cases of puerperal fever reported in the litterature in which the S. pyogenes strains were serotyped supported the hypothesis that R28-expressing strains were overrepresented also among puerperal fever isolates recovered earlier in the 20 th century [24] . Although many S. pyogenes strains isolated from 20 th century cases of puerperal fever probably did not express R28, this finding does not contradict the hypothesis that R28 may favor the emergence of epidemics, because endemic isolates, that cause sporadic cases or small outbreaks, would be expected to be non-clonal, while only epidemic strains would be expected to be clonal [25] .
Molecular characterization of the R28 protein [24] showed that it is a member of a family of extremely repetitive surface proteins first identified in the group B streptococcus (GBS; Streptococcus agalactiae) [26] , which is often found in the normal vaginal flora and causes serious invasive disease in newborns [27] . The protein family that includes R28 was first defined by the GBS proteins Rib and α [26, 28, 29] and among these GBS proteins R28 is most closely related to Rib (Fig. 2) . Indeed, R28 can be viewed as a chimera derived from Rib and two other GBS surface proteins [24] .
These data indicated that the gene encoding R28 may have originated in GBS, a hypothesis supported by the finding that some strains of GBS express a protein virtually identical to R28 [30, 31] The similarity between R28 of S. pyogenes and Rib of GBS suggests that these two streptococcal surface proteins may have similar function. Interestingly, the R28 protein promotes binding of S. pyogenes to a human epithelial cell line of cervical origin [24] , and one can speculate that the Rib protein of GBS has similar function, allowing GBS to colonize the human genital tract. However, attempts to demonstrate that Rib is an adhesin have been unsuccessful so far.
To summarize, the R28 protein of S. pyogenes is epidemiologically associated with cases of puerperal fever and promotes binding to a human cervical cell line derived from the cervix. Interestingly, a bacterial mutant lacking R28 did not bind to these epithelial cells, a finding that led us to hypothesize that the R28 protein confers tissue tropism, specifically promoting adhesion of S. pyogenes to cells in the female genital tract [24] . According to this hypothesis, exposure to an R28-expressing S.
pyogenes strain in connection with child delivery would increase the risk for a serious infection (puerperal fever), because the R28-expressing bacteria can rapidly establish an infection in the wounded tissue. Importantly, strains of S. pyogenes produce potent exotoxins, which probably are required for the development of puerperal fever and other invasive S. pyogenes infections [32] . In contrast, GBS lacks the toxins of S.
pyogenes and may therefore not be able to cause puerperal fever, although it colonizes the female genital tract. Thus, a working model for the molecular pathogenesis of puerperal fever is now emerging.
Vaccine development: a problem with animal models
No vaccine is available against S. pyogenes infections. A priori, the M protein would appear to be a promising vaccine component, because it is expressed by all strains and elicits protective immunity, but the antigenic variation between M proteins expressed by different strains has so far precluded the development of a vaccine. Moreover, possible cross-reactions between M protein and human tissues have caused major concerns [3] . However, work is in progress to develop a multivalent vaccine based on a combination of many different HVRs, which may not elicit unwanted cross-reactivities [33] . Possibly, a vaccine could also be based on the conserved parts of M protein [34, 35] although antibodies directed against this part might be expected to have poor activity because they do not block the antiphagocytic function of the HVR. Another interesting vaccine candidate expressed by all strains of S. pyogenes is ScpA, a surface localized C5a-peptidase that shows a high degree of conservation between strains [36] .
However, little is yet known about the ability of ScpA to elicit protective immunity in a human system. Several other surface proteins are potentially interesting as vaccine components, but have the drawback that they may not be expressed by all strains of S.
pyogenes [24, [37] [38] [39] [40] A major problem in vaccine development is the lack of a good animal model for infections caused by S. pyogenes, a specific human pathogen. In this regard, S.
pyogenes is similar to many other human pathogens. However, a vaccine must first be tested in an animal model, even if the model is poor. This is acceptable, as long as the results are interpreted with caution, but a problem that is sometimes overlooked is that a virulence factor with a key role in human infections may be of little or no importance in an animal model, making results obtained in the animal model of uncertain significance. This problem is well demonstrated by the properties of the S. pyogenes M22 protein (Fig. 1) , which binds human C4BP and IgA-Fc, but does not bind C4BP or
IgA of mouse origin [18, 41] , excluding the use of mice as a model to study M22 and similar M proteins. This type of problem should be kept in mind in evaluating data obtained in the mouse, which is the only animal model commonly used to study the pathogenesis of S. pyogenes infections [42, 43] .
The use of animal models becomes particularly complicated if a pathogen actively interferes with human defenses, as in the M22 system, in which human C4BP
bound to the M protein interferes with complement deposition (Fig. 1) . This problem is presented in a schematic way in Fig. 3 . In the human system, an antibody binding to a bacterial surface antigen may cause complement activation, resulting in opsonization of the bacterium by immunoglobulin (Ig) and complement, resulting in protection of the host against infection (Fig. 3A) . Importantly, efficient opsonization commonly requires both Ig and complement [44] , implying that a microorganism may evade opsonization by interfering with deposition of either Ig or complement. This situation is shown in Fig. 3B , where the bacterium expresses a surface structure that specifically inhibits deposition of human complement. One bacterial surface molecule with these properties is the S. pyogenes M22 protein. In this situation, the human host is poorly protected and infection may ensue. However, if the same bacterium infects an animal host, the bacterial surface protein that interferes with complement deposition will not function, due to its specificity for human complement. Therefore, the bacteria will be opsonized by both Ig and complement and the animal host may be protected, although the bacterium expresses a virulence factor that would allow infection in the human system.
In the case of the S. pyogenes M22 protein, this situation would correspond to the inability of M22 to bind mouse C4BP.
With regard to vaccine development, it is of particular relevance to compare which does not fit into the alignment with Rib. This region can be divided into two subregions, one with homology to the repeat region of the GBS α protein, which belongs to the same family as Rib and R28 [24] , and one with homology to the GBS β protein, which is unrelated to the Rib and α proteins [45, 46] . Thus, the R28 protein can be viewed as a chimera derived from three different GBS proteins [24] . 
